Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.
about
Bacteriophage lysins as effective antibacterialsCharacterizing the modification of surface proteins with poly(ethylene glycol) to interrupt platelet adhesion.Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications.Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogensmicroPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4)Bacteriophage endolysins as novel antimicrobials.Recombinant bacteriophage lysins as antibacterialsIntegrin targeted delivery of radiotherapeutics.Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Gene and protein sequence optimization for high-level production of fully active and aglycosylated lysostaphin in Pichia pastoris.Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance.Peptidoglycan hydrolases-potential weapons against Staphylococcus aureusPEGylating a bacteriophage endolysin inhibits its bactericidal activity.Hydrogen/deuterium exchange mass spectrometry and site-directed disulfide cross-linking suggest an important dynamic interface between the two lysostaphin domains.Osteocompatibility of biofilm inhibitors.Exploiting what phage have evolved to control gram-positive pathogensLysostaphin in treatment of neonatal Staphylococcus aureus infection.Wall teichoic acid deficiency in Staphylococcus aureus confers selective resistance to mammalian group IIA phospholipase A(2) and human beta-defensin 3Sustained anti-staphylococcal effect of lysostaphin in the rabbit aqueous humor.Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.In vitro release--in vivo microbiological and toxicological studies on ketoconazole lipid granules.Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials.Hydrogel delivery of lysostaphin eliminates orthopedic implant infection by Staphylococcus aureus and supports fracture healing.Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials
P2860
Q24648457-CD9C31F0-A668-45FF-BADB-B28084E81615Q33233070-0D138FE5-8182-4E69-9AE2-B033E12B0449Q33664443-1CE3098D-0F48-4FC9-B279-A9A39B3EE70CQ34114172-14205B39-031D-4A9E-82BB-57D8C75101C9Q34282774-BE75AB1F-A759-48E6-BD50-1FA8DFB333D7Q34303439-9003258A-3670-463C-8FA2-83CCAF17025EQ34558237-D2AA9DF5-28DF-44B7-B77C-48D358EE4591Q34912696-A7AF30FF-6201-4894-B72F-266214A511B8Q35638576-C16EFC9D-3ACA-493C-9D2A-5D9B919DCAE6Q35751036-DA1125BC-6FB0-4D9E-BD96-9A6EDB417B4BQ37713110-5AD61AC6-6963-4C84-88A2-0A10B8F9D2BEQ38009935-A5F24CF8-B358-4FE7-A893-06F13C625001Q38053102-E8F3A742-7184-414F-BC07-4E3242EEC95FQ39312418-375EB306-4AC7-4403-B284-EAA97EB8C821Q39766508-58E3FE12-FEC0-4FE1-973B-0F57DF9F0829Q41599948-06082417-C87F-42DA-B622-8138534A1DBCQ42072037-A46D95BD-B506-468C-915F-C2423D0459A5Q42080630-7CF0BF54-69AF-4204-9180-C9373ECF1B5EQ42730621-F4C80106-AA66-45CA-8406-7D3A10D0A486Q43064771-6DF30D8E-A706-4202-94DA-E19787FE7531Q46173172-4E6CA59E-9332-4048-AF53-1977684E4435Q46831439-FE87D36A-74B5-4FFB-8615-AF8C5D160BECQ52642775-1CE7AD08-89E9-4B79-9919-E0A1534B8232Q54212204-B208F73E-0CC9-48C7-A444-D17A9D65B66CQ59128002-BD87D382-14FB-4099-A053-E3BA8CED5573
P2860
Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Improved pharmacokinetics and ...... ugated to polyethylene glycol.
@en
Improved pharmacokinetics and ...... ugated to polyethylene glycol.
@nl
type
label
Improved pharmacokinetics and ...... ugated to polyethylene glycol.
@en
Improved pharmacokinetics and ...... ugated to polyethylene glycol.
@nl
prefLabel
Improved pharmacokinetics and ...... ugated to polyethylene glycol.
@en
Improved pharmacokinetics and ...... ugated to polyethylene glycol.
@nl
P2093
P2860
P1476
Improved pharmacokinetics and ...... ugated to polyethylene glycol.
@en
P2093
Anjali Shah
James Mond
Scott Walsh
P2860
P304
P356
10.1128/AAC.47.2.554-558.2003
P407
P577
2003-02-01T00:00:00Z